Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

Top 10 Copper-producing Companies (Updated 2024)

Could the Silver Price Really Hit US$100 per Ounce? (Updated 2024)

Rare Earths Reserves: Top 8 Countries (Updated 2024)

Where Does Tesla Get its Lithium? (Updated 2024)

Top 10 Countries for Natural Gas Production (Updated 2024)

Hydrogen Stocks: 9 Biggest Companies

Top 5 Junior Gold Stocks on the TSXV in 2024

A State-by-State Guide to Cannabis in Australia

Top Stories This Week: Gold Consolidates as Stagflation Risks Rise, Copper Breaks US$10,000

Trending Press Releases

Indicative, Conditional and Non-Binding Proposal Received by American Rare Earths

Purepoint Uranium Group Inc. Launches Strategic Drill Program at Turnor Lake Project Targeting the La Rocque Structural Corridor

Beyond Lithium and Its Exploration Team Recognized with Bernie Schnieders Discovery of the Year Award

Material Sale of VMware Cloud Platform

Falco Resources: Canadian Explorer in the Rouyn-Noranda Mining Camp

CENTURY LITHIUM ANNOUNCES POSITIVE FEASIBILITY STUDY FOR THE CLAYTON VALLEY LITHIUM PROJECT, NEVADA

More Press Releases
Trending Companies

Jindalee Lithium

JLL:AU

Rio Silver

RYO:CA

Falco Resources

FPC:CC

Freeport-McMoRan

FCX
More Companies
Trending Reports

Lithium Outlook for Australia

2024 Uranium Outlook (Updated for Q2)

2024 Gold Outlook Report

2024 Lithium Market Outlook

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold
Copper
Uranium
Oil and Gas
Artificial Intelligence
Biotech
loader

Minerva Neurosciences

NSD:NERV
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company.
Press Releases
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. The company primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. Targeted disorders include schizophrenia, insomnia, major depressive disorder and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
×